Stocks News

LAST PRICE
71.6400
TODAY'S CHANGE (%)
Trending Down-0.0100 (-0.0140%)

Bid / Lots
71.5900/ 4
Ask / Lots
71.6900/ 1
Open / Previous Close
71.7800 / 71.6500
Day Range
Low 71.3900
High 73.3737
52 Week Range
Low 51.7900
High 89.9100
Volume
238,000
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

No documents available

Today
- Truist Adjusts Insmed PT to $88 From $68, Updates Model Post Commercial Day; Maintains Buy Rating, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: INSM
Jun 27, 2024
- Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating, from 8:59AM ET on Thursday Jun 27, 2024 by MT Newswires
  8:59AM ET on Thursday Jun 27, 2024 by MT Newswires
  Companies Mentioned: IONS
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025, from 8:01AM ET on Thursday Jun 27, 2024 by PR Newswire
  8:01AM ET on Thursday Jun 27, 2024 by PR Newswire
  Companies Mentioned: INSM
Jun 26, 2024
- Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024, from 4:05PM ET on Wednesday Jun 26, 2024 by Business Wire
  4:05PM ET on Wednesday Jun 26, 2024 by Business Wire
  Companies Mentioned: MEDP
- Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172, from 7:15AM ET on Wednesday Jun 26, 2024 by MT Newswires
  7:15AM ET on Wednesday Jun 26, 2024 by MT Newswires
  Companies Mentioned: SRPT
- Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172, from 6:10AM ET on Wednesday Jun 26, 2024 by MT Newswires
  6:10AM ET on Wednesday Jun 26, 2024 by MT Newswires
  Companies Mentioned: SRPT
Jun 25, 2024
- Update: Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review, from 12:58PM ET on Tuesday Jun 25, 2024 by MT Newswires
  12:58PM ET on Tuesday Jun 25, 2024 by MT Newswires
  Companies Mentioned: IONS
- Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review, from 7:55AM ET on Tuesday Jun 25, 2024 by MT Newswires
  7:55AM ET on Tuesday Jun 25, 2024 by MT Newswires
  Companies Mentioned: IONS
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed, from 6:55AM ET on Tuesday Jun 25, 2024 by PR Newswire
  6:55AM ET on Tuesday Jun 25, 2024 by PR Newswire
  Companies Mentioned: IONS
Jun 24, 2024
- Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating, from 12:40PM ET on Monday Jun 24, 2024 by MT Newswires
  12:40PM ET on Monday Jun 24, 2024 by MT Newswires
  Companies Mentioned: SRPT

Bio-Techne Corp
NASDAQ:TECHUnited States

Search Criteria

Peers Headlines

Today

Truist Adjusts Insmed PT to $88 From $68, Updates Model Post Commercial Day; Maintains Buy Rating, from 6 hours ago by MT Newswires

Jun 27, 2024

Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating, from 8:59AM ET on Thursday Jun 27, 2024 by MT Newswires

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025, from 8:01AM ET on Thursday Jun 27, 2024 by PR Newswire

Jun 26, 2024

Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024, from 4:05PM ET on Wednesday Jun 26, 2024 by Business Wire

Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172, from 7:15AM ET on Wednesday Jun 26, 2024 by MT Newswires

Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172, from 6:10AM ET on Wednesday Jun 26, 2024 by MT Newswires

Jun 25, 2024

Update: Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review, from 12:58PM ET on Tuesday Jun 25, 2024 by MT Newswires

Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review, from 7:55AM ET on Tuesday Jun 25, 2024 by MT Newswires

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed, from 6:55AM ET on Tuesday Jun 25, 2024 by PR Newswire

Jun 24, 2024

Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating, from 12:40PM ET on Monday Jun 24, 2024 by MT Newswires